Gamma Frequency Sensory Flicker Stimulation for Brain Inflammation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective, non-invasive means to modulate brain inflammation and immunomodulatory signaling, particularly in neurodegenerative diseases like Alzheimer's, where gamma activity deficits are integral to pathology, and existing approaches do not rapidly induce immune responses.
Innovation Solution
Non-invasive sensory flicker stimulation, specifically at gamma frequencies (20-80 Hz), is used to induce neural activity in the brain, modulating intracellular signaling pathways like MAPK and NFκB, which rapidly upregulate cytokines and chemokines involved in microglial recruitment and activation, thereby addressing inflammation and immune function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-invasive sensory flicker stimulation is used to modulate brain inflammation, then immune response modulation is achieved, but the method is new and unproven compared to conventional pharmaceutical methods
Solution Approach 1:
The patent replaces conventional pharmaceutical methods (chemical substances) with a physical stimulation approach (sensory flicker stimulation) to modulate brain inflammation and immune responses. This substitution of mechanical/physical means for chemical means represents a fundamental paradigm shift in treating neuroinflammatory conditions
2Reliability
If gamma frequency stimulation is applied to recruit microglia and reduce amyloid beta, then neurodegenerative disease treatment is achieved, but the stimulation protocol is complex and requires precise frequency control
Solution Approach 1:
The patent employs specific parameter changes in sensory stimulation (frequency, duration, intensity) to achieve therapeutic effects. By optimizing these parameters, the protocol balances effectiveness in recruiting microglia and reducing amyloid beta with practical implementation considerations
Solution Approach 2:
The stimulation protocol uses periodic sensory flicker at gamma frequencies (20-80 Hz) to drive neural activity and recruit microglial cells. The periodic nature of the stimulation allows for rhythmic activation of immune cells while providing rest intervals, managing overall protocol complexity
3Productivity
If short duration stimulus is used to modulate soluble mediators, then rapid immune response is achieved, but the duration of effect is limited
Solution Approach 1:
The patent applies preliminary action by using short-duration sensory stimulation to trigger rapid immune responses and gene expression changes. The brief stimulation serves as a catalyst that initiates cascading biological effects, achieving rapid modulation of soluble mediators like cytokines and chemokines
Solution Approach 2:
The system incorporates feedback mechanisms where the biological response to stimulation (changes in soluble mediators, gene expression) can inform subsequent stimulation parameters. This feedback loop helps extend and optimize the duration of therapeutic effect while maintaining rapid response capabilities
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively reduces amyloid beta levels, recruits microglia, and induces rapid immune responses, potentially treating neurodegenerative diseases by modulating brain inflammation and immune signaling, offering a novel therapeutic strategy beyond conventional pharmaceutical methods.
Implementation Method 1
Non-invasive sensory flicker stimulation, specifically at gamma frequencies (20-80 Hz), is used to induce neural activity in the brain
Data Source
AI summary
Methods for controlling brain activity in a subject are described herein. An example method can include delivering a stimulus to the subject, wherein the stimulus induces neural activity in the subject's brain and modulates expression of at least one soluble mediator of cellular activity (such as, for example, a cytokine, chemokine, and/or growth factor) within the subject, and the stimulus is delivered to the subject for less than one hour.